
Opinion|Videos|December 14, 2023
Toxicity Management in Patients With R/R MM Receiving CAR T-Cell Therapy
Key opinion leaders review the management of CAR-T therapy side effects in patients with relapsed/refractory multiple myeloma, including cytokine release syndrome and neurotoxicity, and emphasize the importance of early supervision and known toxicity timing.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
3
Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC
4
How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
5


















































































